About Edap Tms S.a.
https://www.edap-tms.comEDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally.
CEO
Ryan Rhodes
Compensation Summary
(Year )
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
SOLEUS CAPITAL MANAGEMENT, L.P.
Shares:7.31M
Value:$29.89M
MORGAN STANLEY
Shares:3.36M
Value:$13.75M
ROCK SPRINGS CAPITAL MANAGEMENT LP
Shares:1.27M
Value:$5.19M
Summary
Showing Top 3 of 43
About Edap Tms S.a.
https://www.edap-tms.comEDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $13.88M ▼ | $10.9M ▼ | $-5.01M ▲ | -36.13% ▼ | $-0.13 ▲ | $-4.22M ▲ |
| Q2-2025 | $16.04M ▲ | $12.59M ▲ | $-5.6M ▲ | -34.91% ▲ | $-0.15 ▲ | $-5.13M ▲ |
| Q1-2025 | $13.56M ▼ | $11.69M ▼ | $-7.07M ▼ | -52.18% ▼ | $-0.19 ▼ | $-5.35M ▼ |
| Q4-2024 | $20.32M ▲ | $12.84M ▲ | $-1.94M ▲ | -9.55% ▲ | $-0.05 ▲ | $-3.1M ▲ |
| Q3-2024 | $13.1M | $10.99M | $-6.4M | -48.85% | $-0.17 | $-5.35M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $10.57M ▼ | $61.46M ▼ | $38.14M ▼ | $23.32M ▼ |
| Q2-2025 | $16.27M ▼ | $68.34M ▼ | $40.52M ▲ | $27.82M ▼ |
| Q1-2025 | $22.82M ▼ | $74.98M ▼ | $40.52M ▼ | $34.46M ▼ |
| Q4-2024 | $29.84M ▲ | $86.06M ▲ | $45.17M ▲ | $40.9M ▼ |
| Q3-2024 | $25.48M | $79.04M | $36.4M | $42.64M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▼ | $0 | $0 ▲ |
| Q2-2025 | $-6.35M ▲ | $-4.66M ▲ | $-1.6M ▼ | $60.94K ▲ | $0 ▲ | $-6.26M ▲ |
| Q1-2025 | $-7.45M ▼ | $-5.34M ▼ | $-1.3M ▼ | $-1.25M ▼ | $-30.9M ▼ | $-6.64M ▼ |
| Q4-2024 | $-2.07M ▲ | $0 ▲ | $0 ▲ | $0 ▼ | $30.9M ▲ | $0 ▲ |
| Q3-2024 | $-6.4M | $-4.86M | $-979K | $614K | $-30.21M | $-5.84M |
Revenue by Products
| Product | Q4-2016 | Q4-2018 | Q2-2018 | Q1-2020 |
|---|---|---|---|---|
 Licenses and Others | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Product and Service Other | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 HIFU Treatments and Devices Leased | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Parts and Services | $0 ▲ | $10.00M ▲ | $0 ▼ | $0 ▲ |
 Product | $0 ▲ | $30.00M ▲ | $10.00M ▼ | $0 ▼ |
 High Intensity Focused Ultrasound HIFU | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Urology Devices and Services UDS | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
Revenue by Geography
| Region | Q1-2020 |
|---|---|
 Asia | $20.00M ▲ |
 FRANCE | $10.00M ▲ |
 Other Geographical Areas | $10.00M ▲ |
 UNITED STATES | $10.00M ▲ |
CEO
Ryan Rhodes
Compensation Summary
(Year )
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
SOLEUS CAPITAL MANAGEMENT, L.P.
Shares:7.31M
Value:$29.89M
MORGAN STANLEY
Shares:3.36M
Value:$13.75M
ROCK SPRINGS CAPITAL MANAGEMENT LP
Shares:1.27M
Value:$5.19M
Summary
Showing Top 3 of 43